AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 180 filers reported holding AERIE PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.50 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $1,757,000 | -62.7% | 36,980 | -51.7% | 0.49% | -63.7% |
| Q3 2018 | $4,711,000 | +7.9% | 76,537 | +18.4% | 1.36% | -12.6% |
| Q2 2018 | $4,367,000 | +95.6% | 64,655 | +57.1% | 1.55% | +8.3% |
| Q1 2018 | $2,233,000 | +17.0% | 41,157 | +28.8% | 1.43% | -7.4% |
| Q4 2017 | $1,909,000 | +82.5% | 31,956 | +48.5% | 1.55% | +43.8% |
| Q3 2017 | $1,046,000 | – | 21,526 | – | 1.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 805,217 | $14,212,000 | 4.99% |
| DAFNA Capital Management LLC | 156,842 | $2,768,000 | 2.34% |
| NORTHPOINTE CAPITAL LLC | 1,034,400 | $18,257,000 | 2.15% |
| HARVEY CAPITAL MANAGEMENT INC | 223,200 | $3,856,000 | 1.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,211,644 | $39,036,000 | 1.30% |
| Boulegeris Investments, Inc. | 88,660 | $1,565,000 | 1.12% |
| Partner Investment Management, L.P. | 43,623 | $770,000 | 1.08% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 150,000 | $2,648,000 | 0.92% |
| PFM Health Sciences, LP | 1,851,564 | $32,680,000 | 0.83% |
| Benchmark Capital Advisors | 55,400 | $978,000 | 0.69% |